ALZCHEM GROUP AG (ACT.DE) Fundamental Analysis & Valuation

FRA:ACT • DE000A2YNT30

Current stock price

169.4 EUR
+6 (+3.67%)
Last:

This ACT.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. ACT.DE Profitability Analysis

1.1 Basic Checks

  • In the past year ACT was profitable.
  • In the past year ACT had a positive cash flow from operations.
  • ACT had positive earnings in each of the past 5 years.
  • ACT had a positive operating cash flow in 4 of the past 5 years.
ACT.DE Yearly Net Income VS EBIT VS OCF VS FCFACT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 10.27%, ACT belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 24.76%, ACT belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 13.72%, ACT belongs to the top of the industry, outperforming 95.71% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ACT is significantly above the industry average of 6.88%.
  • The 3 year average ROIC (13.60%) for ACT is below the current ROIC(13.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.27%
ROE 24.76%
ROIC 13.72%
ROA(3y)9.87%
ROA(5y)8.8%
ROE(3y)24.16%
ROE(5y)24.97%
ROIC(3y)13.6%
ROIC(5y)11.74%
ACT.DE Yearly ROA, ROE, ROICACT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 11.29%, ACT belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
  • ACT's Profit Margin has improved in the last couple of years.
  • ACT has a better Operating Margin (16.87%) than 87.14% of its industry peers.
  • In the last couple of years the Operating Margin of ACT has grown nicely.
  • With an excellent Gross Margin value of 67.97%, ACT belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACT has grown nicely.
Industry RankSector Rank
OM 16.87%
PM (TTM) 11.29%
GM 67.97%
OM growth 3Y35.88%
OM growth 5Y14.09%
PM growth 3Y26.76%
PM growth 5Y16.8%
GM growth 3Y11.38%
GM growth 5Y1.65%
ACT.DE Yearly Profit, Operating, Gross MarginsACT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. ACT.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ACT is creating value.
  • Compared to 1 year ago, ACT has less shares outstanding
  • The number of shares outstanding for ACT has been reduced compared to 5 years ago.
  • Compared to 1 year ago, ACT has an improved debt to assets ratio.
ACT.DE Yearly Shares OutstandingACT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
ACT.DE Yearly Total Debt VS Total AssetsACT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ACT has an Altman-Z score of 4.96. This indicates that ACT is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.96, ACT belongs to the best of the industry, outperforming 94.29% of the companies in the same industry.
  • ACT has a debt to FCF ratio of 1.13. This is a very positive value and a sign of high solvency as it would only need 1.13 years to pay back of all of its debts.
  • ACT has a Debt to FCF ratio of 1.13. This is amongst the best in the industry. ACT outperforms 92.86% of its industry peers.
  • ACT has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • ACT has a Debt to Equity ratio of 0.14. This is in the better half of the industry: ACT outperforms 72.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 1.13
Altman-Z 4.96
ROIC/WACC1.88
WACC7.31%
ACT.DE Yearly LT Debt VS Equity VS FCFACT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • ACT has a Current Ratio of 2.49. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 2.49, ACT is doing good in the industry, outperforming 78.57% of the companies in the same industry.
  • A Quick Ratio of 1.52 indicates that ACT should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.52, ACT is in the better half of the industry, outperforming 70.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 1.52
ACT.DE Yearly Current Assets VS Current LiabilitesACT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ACT.DE Growth Analysis

3.1 Past

  • ACT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
  • ACT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.48% yearly.
  • The Revenue has been growing slightly by 1.42% in the past year.
  • The Revenue has been growing by 8.19% on average over the past years. This is quite good.
EPS 1Y (TTM)18.57%
EPS 3Y28.42%
EPS 5Y26.48%
EPS Q2Q%13.74%
Revenue 1Y (TTM)1.42%
Revenue growth 3Y1.21%
Revenue growth 5Y8.19%
Sales Q2Q%-1.26%

3.2 Future

  • Based on estimates for the next years, ACT will show a very strong growth in Earnings Per Share. The EPS will grow by 26.32% on average per year.
  • ACT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.01% yearly.
EPS Next Y5.53%
EPS Next 2Y15.99%
EPS Next 3Y26.32%
EPS Next 5YN/A
Revenue Next Year7.47%
Revenue Next 2Y12.07%
Revenue Next 3Y12.68%
Revenue Next 5Y11.01%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ACT.DE Yearly Revenue VS EstimatesACT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ACT.DE Yearly EPS VS EstimatesACT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

3

4. ACT.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 26.89, the valuation of ACT can be described as expensive.
  • ACT's Price/Earnings ratio is in line with the industry average.
  • ACT is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.70, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 26.11, which means the current valuation is very expensive for ACT.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ACT indicates a slightly more expensive valuation: ACT is more expensive than 64.29% of the companies listed in the same industry.
  • ACT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.89
Fwd PE 26.11
ACT.DE Price Earnings VS Forward Price EarningsACT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACT is valued a bit more expensive than the industry average as 61.43% of the companies are valued more cheaply.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACT is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 43.97
EV/EBITDA 13.97
ACT.DE Per share dataACT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACT does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of ACT may justify a higher PE ratio.
  • A more expensive valuation may be justified as ACT's earnings are expected to grow with 26.32% in the coming years.
PEG (NY)4.86
PEG (5Y)1.02
EPS Next 2Y15.99%
EPS Next 3Y26.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ACT.DE Dividend Analysis

5.1 Amount

  • ACT has a Yearly Dividend Yield of 1.29%. Purely for dividend investing, there may be better candidates out there.
  • ACT's Dividend Yield is slightly below the industry average, which is at 2.33.
  • ACT's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.29%

5.2 History

  • On average, the dividend of ACT grows each year by 19.13%, which is quite nice.
Dividend Growth(5Y)19.13%
Div Incr Years5
Div Non Decr Years5
ACT.DE Yearly Dividends per shareACT.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 28.66% of the earnings are spent on dividend by ACT. This is a low number and sustainable payout ratio.
  • The dividend of ACT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP28.66%
EPS Next 2Y15.99%
EPS Next 3Y26.32%
ACT.DE Yearly Income VS Free CF VS DividendACT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M
ACT.DE Dividend Payout.ACT.DE Dividend Payout, showing the Payout Ratio.ACT.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ACT.DE Fundamentals: All Metrics, Ratios and Statistics

ALZCHEM GROUP AG

FRA:ACT (3/13/2026, 7:00:00 PM)

169.4

+6 (+3.67%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners41.61%
Inst Owner ChangeN/A
Ins Owners28%
Ins Owner ChangeN/A
Market Cap1.72B
Revenue(TTM)562.12M
Net Income(TTM)63.46M
Analysts87.27
Price Target180.48 (6.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.29%
Yearly Dividend1.79
Dividend Growth(5Y)19.13%
DP28.66%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.82%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.27%
EPS NY rev (3m)-7.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.43%
Revenue NY rev (3m)-1.96%
Valuation
Industry RankSector Rank
PE 26.89
Fwd PE 26.11
P/S 3.07
P/FCF 43.97
P/OCF 12.59
P/B 6.73
P/tB 6.82
EV/EBITDA 13.97
EPS(TTM)6.3
EY3.72%
EPS(NY)6.49
Fwd EY3.83%
FCF(TTM)3.85
FCFY2.27%
OCF(TTM)13.46
OCFY7.95%
SpS55.22
BVpS25.18
TBVpS24.83
PEG (NY)4.86
PEG (5Y)1.02
Graham Number59.74
Profitability
Industry RankSector Rank
ROA 10.27%
ROE 24.76%
ROCE 19.01%
ROIC 13.72%
ROICexc 16.03%
ROICexgc 16.16%
OM 16.87%
PM (TTM) 11.29%
GM 67.97%
FCFM 6.98%
ROA(3y)9.87%
ROA(5y)8.8%
ROE(3y)24.16%
ROE(5y)24.97%
ROIC(3y)13.6%
ROIC(5y)11.74%
ROICexc(3y)15.49%
ROICexc(5y)13.01%
ROICexgc(3y)15.65%
ROICexgc(5y)13.15%
ROCE(3y)18.84%
ROCE(5y)16.26%
ROICexgc growth 3Y18.84%
ROICexgc growth 5Y13.25%
ROICexc growth 3Y18.94%
ROICexc growth 5Y13.21%
OM growth 3Y35.88%
OM growth 5Y14.09%
PM growth 3Y26.76%
PM growth 5Y16.8%
GM growth 3Y11.38%
GM growth 5Y1.65%
F-Score7
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 1.13
Debt/EBITDA 0.3
Cap/Depr 366.97%
Cap/Sales 17.4%
Interest Coverage 54.63
Cash Conversion 112.78%
Profit Quality 61.81%
Current Ratio 2.49
Quick Ratio 1.52
Altman-Z 4.96
F-Score7
WACC7.31%
ROIC/WACC1.88
Cap/Depr(3y)203.37%
Cap/Depr(5y)168.11%
Cap/Sales(3y)9.66%
Cap/Sales(5y)8.22%
Profit Quality(3y)109.03%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y28.42%
EPS 5Y26.48%
EPS Q2Q%13.74%
EPS Next Y5.53%
EPS Next 2Y15.99%
EPS Next 3Y26.32%
EPS Next 5YN/A
Revenue 1Y (TTM)1.42%
Revenue growth 3Y1.21%
Revenue growth 5Y8.19%
Sales Q2Q%-1.26%
Revenue Next Year7.47%
Revenue Next 2Y12.07%
Revenue Next 3Y12.68%
Revenue Next 5Y11.01%
EBIT growth 1Y20.86%
EBIT growth 3Y37.52%
EBIT growth 5Y23.43%
EBIT Next Year45.22%
EBIT Next 3Y32.94%
EBIT Next 5Y22.28%
FCF growth 1Y-36.78%
FCF growth 3YN/A
FCF growth 5Y14.56%
OCF growth 1Y30.31%
OCF growth 3YN/A
OCF growth 5Y22.98%

ALZCHEM GROUP AG / ACT.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?

ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.


What is the valuation status for ACT stock?

ChartMill assigns a valuation rating of 3 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Overvalued.


Can you provide the profitability details for ALZCHEM GROUP AG?

ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for ACT stock?

The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.


What is the earnings growth outlook for ALZCHEM GROUP AG?

The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 5.53% in the next year.